Kling Bio has entered a partnership and licence option agreement with Sanofi to discover neutralising antibodies and epitopes.
The partnership will leverage Kling Bio's screening platform, Kling-Select, for discovering immuno-functional and hard-to-find antibodies from immortalised human B cells.
Kling-Select has been clinically and commercially validated and plays a crucial role in identifying potent neutralising antibodies.
Using patient-derived B cells, the platform facilitates the rapid detection of antibodies and preserved viral epitopes, improving the design of vaccines and therapeutics.
It employs a function-first screening workflow to reveal rare and effective immune targets, thereby fast-tracking the next-generation prophylactics and treatments development.
The partnership aims to detect and characterise monoclonal antibodies with strong neutralising activity against clinically relevant human viral pathogens.
Through this joint effort, both companies aim to gain insights that could lead to breakthroughs in antiviral therapeutics as well as contribute information towards designing more vaccines.
Kling Bio CEO Michael Koslowski stated: “This collaboration with Sanofi highlights the broad potential of our Kling-Select platform to address global health challenges by enabling the discovery of first-in-class, human-derived antibodies.
“Kling-Select provides a powerful window into the human immune response and accelerates the identification of functional antibodies and novel epitopes. We are excited to combine our expertise with Sanofi’s leadership in vaccine development to advance next-generation therapeutics and vaccines.”
Kling-Select has been utilised recently on peripheral and tumour-infiltrating B cells obtained from cancer patients, resulting in a collection of new antibody-target pairs.
In July 2025, Sanofi announced a $25m investment in Adagene, providing the company with the necessary funds to support its research and development initiatives, including the clinical development of muzastotug (ADG126).
